In a report released today, Ami Fadia from Needham maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $28.00.
Ami Fadia’s rating is based on several positive indicators for ACADIA Pharmaceuticals. The company’s recent earnings release showed sales guidance aligning well with market expectations, reflecting a stable financial outlook. Additionally, the management’s commitment to investing in brand development and expanding their team outside the U.S. suggests a strategic approach to growth.
A key factor in the Buy rating is the improvement in commercial metrics for Daybue, with a notable reduction in discontinuation rates and an increase in the average dose usage. Furthermore, the expansion of the diagnosed Rett population is promising for future sales. The anticipation of data readouts in 2026 for their pipeline products also adds to the potential for long-term growth, making ACADIA an attractive investment opportunity.
In another report released today, JMP Securities also reiterated a Buy rating on the stock with a $37.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com